EyeGate Pharmaceuticals, Inc. (EYEG) Financials

$36.17

south_east
-$0.04 (-0.1%)
Day's range
$36.17
Day's range
$36.17

EYEG Income statement / Annual

Last year (2024), AB Corporate Bond ETF's total revenue was $16.02 M, and the percentage change from the previous year is not available. In 2024, AB Corporate Bond ETF's net income was $7.72 M. See AB Corporate Bond ETF,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024
Period Ended 12/31/2024
Operating Revenue $16.02 M
Cost of Revenue $0.00
Gross Profit $16.02 M
Gross Profit Ratio 1
Research and Development Expenses $7.84 M
General & Administrative Expenses $5.54 M
Selling & Marketing Expenses $0.00
Selling, General & Administrative Expenses $5.54 M
Other Expenses $0.00
Operating Expenses $13.38 M
Cost And Expenses $13.38 M
Interest Income $1.25 M
Interest Expense -$21.45 K
Depreciation & Amortization $0.00
EBITDA $0.00
EBITDA Ratio 0
Operating Income Ratio 0.16
Total Other Income/Expenses Net $3.02 M
Income Before Tax $5.66 M
Income Before Tax Ratio 0.35
Income Tax Expense -$2.07 M
Net Income $7.72 M
Net Income Ratio 0.48
EPS 1.99
EPS Diluted 1.87
Weighted Average Shares Out $3.87 M
Weighted Average Shares Out Diluted $4.13 M
Link